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Abstract
Objective: Although enzyme replacement therapy (ERT) is a highly effective therapy, CRIM-negative (CN) infantile Pompe
disease (IPD) patients typically mount a strong immune response which abrogates the efficacy of ERT, resulting in clinical
decline and death. This study was designed to demonstrate that immune tolerance induction (ITI) prevents or diminishes
the development of antibody titers, resulting in a better clinical outcome compared to CN IPD patients treated with ERT
monotherapy.
Methods: We evaluated the safety, efficacy and feasibility of a clinical algorithm designed to accurately identify CN IPD
patients and minimize delays between CRIM status determination and initiation of an ITI regimen (combination of
rituximab, methotrexate and IVIG) concurrent with ERT. Clinical and laboratory data including measures of efficacy analysis
for response to ERT were analyzed and compared to CN IPD patients treated with ERT monotherapy.
Results: Seven CN IPD patients were identified and started on the ITI regimen concurrent with ERT. Median time from
diagnosis of CN status to commencement of ERT and ITI was 0.5 months (range: 0.1–1.6 months). At baseline, all patients
had significant cardiomyopathy and all but one required respiratory support. The ITI regimen was safely tolerated in all
seven cases. Four patients never seroconverted and remained antibody-free. One patient died from respiratory failure. Two
patients required another course of the ITI regimen. In addition to their clinical improvement, the antibody titers observed
in these patients were much lower than those seen in ERT monotherapy treated CN patients.
Conclusions: The ITI regimen appears safe and efficacious and holds promise in altering the natural history of CN IPD by
increasing ERT efficacy. An algorithm such as this substantiates the benefits of accelerated diagnosis and management of
CN IPD patients, thus, further supporting the importance of early identification and treatment initiation with newborn
screening for IPD.
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Introduction
Pompe disease (OMIM 232300; acid maltase deficiency,
glycogen storage disease type II) is an autosomal recessive
deficiency of lysosomal acid alpha-glucosidase (GAA; OMIM
606800) that results in progressive glycogen accumulation [1].
Classic infantile Pompe disease (IPD) is characterized by
cardiomegaly, respiratory insufficiency, and profound hypotonia.
Without treatment, death secondary to cardiorespiratory failure
occurs prior to two years of age [2]. Enzyme replacement therapy
(ERT) with recombinant human acid alpha glucosidase (rhGAA;
alglucosidase alfa) has been commercially available since 2006,
and has led to improved clinical outcome measures, including
prolonged overall and ventilator-free survival in IPD patients [3–
6]. While such improvements have been noted initially for the IPD
population as a whole, marked variability and long-term
unpredictability in treatment response remains a challenge. A
host of endogenous and exogenous factors are believed to account
for this, but have yet to be completely elucidated. Given the rapid
disease progression, early diagnosis and treatment are critical, as
even slight delays can result in a significantly altered clinical course
[6,7].
Despite some gaps in knowledge, certain factors have been
identified as having prognostic value in IPD, most prominent
among them being cross-reactive immunologic material (CRIM)
status. CRIM-negative (CN) patients with two deleterious muta-
tions and no GAA protein expression experience an initial
response to ERT before entering a phase of devastating clinical
decline at rate that approximates that observed in untreated IPD
[8]. This clinical decline in CN cases is largely due to the
development of high sustained anti-rhGAA antibody titers
(HSAT). While there are some exceptions in which CRIM-
positive (CP) patients develop HSAT and experience clinical
decline similar to CN patients, the majority of CP patients with
missense mutations and some residual GAA protein either do not
mount an immune response or mount a transient low titer
response, and exhibit a more favorable response to ERT
monotherapy [8,9].
Evidence from long-term clinical experience with four CN IPD
patients has demonstrated successful immune tolerance induction
(ITI) with a regimen of rituximab (RTX) and methotrexate (MTX)
6 intravenous immunoglobulin (IVIG) in the treatment-naı¨ve
(n = 2) or early ERT (n = 2) setting [10,11]. Patients in whom anti-
rhGAA antibody titers were essentially eliminated showed greatly
improved clinical response to ERT, thus demonstrating the great
clinical utility of such immunomodulatory protocols in the
management of IPD [10]. However, a significant difference
between the naı¨ve patients and those already receiving ERT was
the amount of immune modulation needed: patients already
receiving ERT prior to the initiation of immune modulation
required prolonged immune modulation [10]. In another two
CRIM-negative cases with an entrenched immune response,
immune suppression was unsuccessful despite multiple attempts
over several years with different agents [12,13]. Although clinical
experience and current literature on the use of ITI protocols are
greatly limited, success is more likely when immune modulation is
started at the onset of ERT (ERT-naı¨ve setting) [14]. Yet, there is
no established algorithm which clearly delineates the most efficient
pathway for treatment once a diagnosis of CN IPD is made. Here,
we describe an algorithm for rapid diagnosis and management of
CN IPD, and demonstrate successful ITI with a regimen of
rituximab, methotrexate 6 intravenous immunoglobulin in the
ERT-naı¨ve setting. We also evaluate the effectiveness of this
algorithm by examining clinical outcomes seen in the CN patients
treated with ERT+ITI versus CN patients treated with ERT
monotherapy.
Patients and Methods
Patient Identification and Algorithm for Rapid CRIM
Status Determination and ITI Treatment
As part of our existing Duke Institutional Review Board (IRB)-
approved study (Pro00001562; NCT01665326, www.clinicaltrials.
gov), written informed consent was obtained by telephone from
the patients’ parent(s) or legal guardian(s) for determination of
CRIM status and long-term follow-up of each patient. The
patient’s local physician acted as a third party witness to the
telephone consent. The consent form was signed by the parent(s)/
legal guardian(s) and returned via email or fax to the Duke study
staff for his/her signature. A copy of the fully signed consent form
was returned to the parent(s)/legal guardian(s). An algorithm for
the rapid diagnosis and timely initiation of ITI was developed and
implemented specifically for CN IPD patients (Figure 1). As per
the algorithm, upon diagnostic confirmation of IPD, CN status
was rapidly inferred by mutation analysis, using an established
mutation database, which has allowed prediction of CN status in
more than 90% cases [15] CRIM negative status was further
confirmed using western blot analysis on skin fibroblast cell
extracts, if none of the GAA protein processing forms (unprocessed
precursor band at 110 kDa or processed forms bands at 95, 76 and
70 kDa) were detected (Figure 2) [8].
Once CN status was confirmed, the ITI component of this
algorithm was implemented along with the initiation of ERT,
either as standard of care or after the approval by the respective
IRB or ethics committees based on institutional policies. This
involved providing all treating physicians with an ITI protocol that
included a regimen of rituximab (four weekly doses intravenously)
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and methotrexate (three doses per week for three weeks
subcutaneously), with or without monthly IVIG (Figure 3).
Specific details of the ITI regimen for each patient are shown in
Table 1 and are similar to two previously published cases [10].
Based on the algorithm, patients with antibody titers of $6,400 at
two or more time time-points and CD19 positive B-cell%
(CD19%) recovery at $5 months were administered another
cycle of the same ITI regimen. Patients received alglucosidase alfa
(MyozymeH/LumizymeH) manufactured by Genzyme Corpora-
tion (Cambridge, MA) at cumulative doses of 20 mg/kg,
administered by infusion every other week based on MyozymeH
package insert, or weekly, based on clinical judgment of the
treating physicians.
Clinical Parameters
Baseline and follow-up data pertaining to cardiac, respiratory,
motor, and feeding statuses were serially evaluated by healthcare
professionals at the respective institutions through October 2012,
Figure 1. An algorithm for the management of cross-reactive immunologic material (CRIM)-negative (CN) infantile Pompe disease
patients. *Institutional review board (IRB) approved study (NCT01665326; www.clinicaltrials.gov) for rapid determination of CRIM status and long-
term follow-up of response to treatment and ITI in Pompe disease. {CN status determination from an established CRIM negative mutation database,
which allows prediction of CN status in more than 90% cases [15]. `ITI regimen is shown in Figure 2. 1Based on the literature antibody titers sustained
at $6,400 results in a suboptimal therapeutic response to ERT. For that reason, 6,400 was used a cutoff for further intervention [9,19]. **Based on the
half-life of rituximab, CD19% recovery is typically noted around 5 months. {{The decision to repeat the same ITI regimen (figure 3) or to administer ITI
with a plasma-cell-targeting agent [20] should be based on multiple factors including, but not limited to, patients clinical status, CD19% and Fcc
receptor polymorphism. ``ITI regimen with plasma cell targeting agent such as bortezomib has been described previously [20].
doi:10.1371/journal.pone.0067052.g001
Figure 2. Representative Western gel blot showing CRIM
negative status of four patients (lanes 3–6). Lane 1- protein
magic marker; lane 8 -CRIM negative control cell line; lane 10 - normal
human fibroblast (NHF) control; Lanes 2, 7 and 9 - left empty. 20 ug of
skin fibroblast cell protein extract was loaded for each patient lane and
2.5 ug protein was loaded for NHF. Western blot was probed with anti-
GAA antibody and ß-Actin was used as a protein loading control.
doi:10.1371/journal.pone.0067052.g002
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at which time the database was locked except invasive ventilator
free survival which was last evaluated in January 2013. Two-
dimensional, M-mode, and Doppler echocardiography were used
to assess left ventricular mass index (LVMI).
Laboratory Parameters
Anti-rhGAA antibodies: Anti-rhGAA IgG antibodies were
assessed by Genzyme Corp. (Framingham, MA) at baseline and
at regular intervals throughout treatment. Antibody status was
ascertained using enzyme-linked immunosorbent assays and
confirmed using radioimmunoprecipitation as described previous-
ly [5].
Safety
Safety was assessed by CD19%, frequency of infections, and
number of infections requiring hospital admission at or around the
time of ITI administration and routine blood tests. Flow cytometry
was used to assess CD19%, using standard techniques at each local
institution.
Comparison of CN Patients Treated with ERT+ITI with CN
Patients Treated with ERT Monotherapy
We compared invasive ventilator free survival, antibody titers
and LVMI values at different time points with the CN ERT+ITI
treated patients described here to CN cases treated with ERT
monotherapy [8,9].
Statistical Analysis
Survival data were analyzed using the Kaplan–Meier method
with two-tailed P values generated using the log-rank test [16].
Other reported P values were generated by the Wilcoxon rank
sum test for continuous variables. Analyses were performed with
STATA version 11.0 (StataCorp LP, College Station, Texas).
Because of the limited sample size, all group outcome variable data
are presented as medians.
Results
Patient Identification and Algorithm for Rapid CRIM
Status Determination and ITI Treatment
Seven CN IPD patients were identified at six different
institutions in three countries. Through application of this
algorithm, CN status was rapidly identified through GAA mutation
analysis, and subsequently confirmed by western blot analysis of
skin fibroblast cells in all seven patients. Demographic information
and mutation data for each patient are shown in Table 1. Median
age at diagnosis of Pompe disease and CRIM-negative status was
2.5 months (range: 10 days-5.5 months). Due to the ability to
predict CN status through mutation analysis alone, there was
minimal delay in treatment initiation. Indeed, the delay was
primarily due to administrative or regulatory issues (i.e., IRB/
ethics committee approval, procurement of resources) rather than
to CRIM status determination. The median duration between CN
diagnosis and start of treatment was 0.5 months (15 days; range –
0.1 months-1.6 months). Median age at start of ITI in conjunction
with ERT was 3.5 months (range: 12 days-6.5 months). In all
cases, the ITI regimen in Figure 3 was used with minor
modifications (Table 1). All patients received alglucosidase alfa
(MyozymeH/LumizymeH) supplied by Genzyme Corporation
(Cambridge, MA) at cumulative doses of 20 mg/kg, administered
by infusion every other week (n = 6) or every week (n = 1, patient 4)
for a median duration of 79 weeks (range: 48–101 weeks).
Clinical Parameters
At baseline (prior to start of ERT and ITI regimen; median age:
3.5 months; range: 0.4 months-6.5 months), all patients had
increased LVMI (Median: 317 g/m2; range: 160–446 g/m2)
Figure 3. ITI treatment regimen which includes rituximab, methotrexate and intravenous immunoglobulin (IVIG). This short course of
ITI regimen (5 weeks) needs to be started together with the first dose of ERT. IVIG is administered on a monthly basis for a period of 5–6 months.
doi:10.1371/journal.pone.0067052.g003
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(Table 2, Figure 4). Of the seven patients, three were invasively
ventilated, two required supplemental oxygen, one required bi-
level positive airway pressure (BiPAP) and one patient required no
respiratory support. Clinical parameters over time are shown in
Table 2. The median LVMI at the last available time-point was
83 g/m2 (range: 64–165 g/m2) after treatment with ERT for a
median of 75 weeks (range: 36–89 weeks of ERT; n = 7),
considerably lower than it was at baseline (median: 317 g/m2;
range: 160–446 g/m2, n = 7) (Figure 4). One of the seven patients
(patient 7) required invasive ventilation and subsequently died due
to respiratory failure and progressive Pompe disease complications
at age 15 months. For the remaining six patients at their most
recent assessment, two required no respiratory support, three
required BiPAP only at night (of which two required supplemental
oxygen), and one patient requiring invasive ventilation at baseline
was able to come off of the ventilator for 10–12 hours each day
(Table 2).
Laboratory Parameters
Details on laboratory parameters are shown in Table 3. Four
patients (Patients 1, 2, 3 and 4) never seroconverted and remained
antibody-free (n = 4; median: 90.5 weeks of ERT; range: 70–101
weeks on ERT) as shown in Table 3. For the remaining three
patients (patients 4, 6 and 7), the median peak antibody titer was
1,600 (week 39; patient 7) and 6,400 (weeks 31 and 23 of ERT;
patients 5 and 6, respectively) and last available antibody titers
were 800 (week 46; patient 7), 3,200 (week 59; patient 5), and
6,400 (week 51; patient 6). Based on the algorithm (Figure 1), two
patients with antibody titers of 6,400 (patients 5 and 6) received a
second treatment course of the same ITI regimen: one patient
(patient 5) had a drop in titer value to 3,200 and the second patient
(patient 6) had antibody titers maintained at 6,400 at database
lock.
Safety
Details on safety related data are shown in Table 3. Only one
patient required hospitalization at any time due to infection at or
around the time of administration of the ITI regimen: patient 3
developed bronchitis with fever and rash, presumably related to a
viral infection, and recovered quickly with no complications. One
patient (patient 7) died due to respiratory failure and progressive
IPD-related complications that did not appear to be directly
related to complications of the ITI protocol. In all cases (n = 6),
CD19% dropped to 0 within 2–5 weeks of starting ITI. There was
complete recovery of CD19% for the four patients with sufficient
follow-up data available (Table 3), three of whom remained anti-
rhGAA antibody-free despite CD19 recovery (patients 1, 2 and 3).
For one of the patients, CD19% was not measured (patient 4). For
the remaining two patients (Patients 5 and 6) there was CD19%
recovery along with a small increase in antibody titer, as described
earlier, and a second treatment course of the same ITI regimen
resulted in the CD19% dropping to 0% (Table 3). There was no
decrease in hemoglobin, white cell counts or increase in liver
enzymes during the time these patients received ITI.
Comparison of CN Patients Treated with ERT+ITI with CN
Patients Treated with ERT Monotherapy
All 11 CN patients from a previous study in which they were
treated with ERT monotherapy either died or became invasive
ventilator dependent by 27.1 months of age [8] versus 1 patient in
the ITI+ERT group in this study, who became invasive ventilator
dependent and subsequently died at the age of 14.5 months. In
terms of invasive ventilator-free survival, there was a statistically
significant difference between the CN ERT monotherapy group
and CN ERT+ITI group (p = 0.0018; Figure 5). Comparison of
antibody titers over time between the two groups shows a clear
difference in antibody titers at different time points (Figure 6).
None of the CN patients treated with ERT monotherapy were
Figure 4. Comparison of median left ventricular mass index (LVMI) values seen over time in CRIM-negative (CN) ERT monotherapy
(n=11) versus CN ERT+ITI (n =7) treated patients. The upper limit of normal LVMI is 64 g/m2 (represented by a horizontal dashed line).
doi:10.1371/journal.pone.0067052.g004
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invasively ventilated at baseline, whereas three CN patients treated
with ITI+ERT in this study were invasively ventilated at baseline
and, remarkably, all were able to come off of invasive ventilation.
When comparing LVMI values over time between the two
groups, CN ERT+ITI (n = 7; median: 317 g/m2; range: 160–
446 g/m2) treated group had a higher median LVMI value at
baseline (p = 0.02; Figure 4), as compared to CN ERT monother-
apy treated group (n = 10; median: 202.58 g/m2; range: 89–
308 g/m2). Both groups had improvement in LVMI for the first
26 weeks [P = 0.26; median LVMI for CN ERT monotherapy
treated group (n = 10): 104.15 g/m2, range: 56.7–269 g/m2;
median LVMI for CN ERT+ITI treated group (n = 7): 127 g/
m2, range: 108–212 g/m2], after which there was progression of
cardiomyopathy in the CN ERT monotherapy group. In contrast,
there was steady improvement in cardiomyopathy for the CN
ERT+ ITI treated group (Figure 4). There was a statistically
significant difference at week 64 [p = 0.03; Median LVMI for CN
ERT monotherapy treated group (n = 3): 149.4 g/m2, range:
96.1–189.8 g/m2, CN ERT+ITI treated group (n = 4); 75 g/m2,
range: 65.1–92.7 g/m2; Figure 4].
Discussion
Results of this study show that the algorithm described herein is
both feasible and effective for optimizing benefit from ERT by
rapidly diagnosing CRIM-negative patients with IPD and starting
ITI along with ERT at the earliest possible time point. CN status
was determined by mutation analysis alone in all seven cases, with
a turnaround time of 48–72 hours. Approximately 90% of all CN
patients can be successfully diagnosed by GAA mutation analysis
alone [15]; in uncertain cases, western blot analysis can be used in
conjunction for final CRIM status determination. As more GAA
mutations become known, this percentage of cases identified as
CN solely by mutation analysis will continue to grow. Moreover,
and more importantly, the whole process of CRIM status
prediction can be completed in less than a week with proper
planning and coordination, as is demonstrated by the cases herein.
In our seven cases from around the world, the quick turnaround
time of CRIM status determination allowed for start of treatment
with ITI plus ERT within 0.5 months (15 days; range: 0.1 months-
1.6 months) of CN status determination. Timely introduction of an
ITI regimen, such as the one we detailed herein, presents a
significant opportunity to further improve the natural history of
CN patients with IPD treated with ERT who would otherwise
remain at risk of developing HSAT and subsequent clinical
decline.
Once a CN patient is identified, the ITI component of the
algorithm can be implemented worldwide on an outpatient basis
in appropriately-equipped institutions. Findings from this study
support a good overall safety and efficacy profile using rituximab,
methotrexate and IVIG for ITI in the ERT-naı¨ve setting, despite
limited numbers. Five of the seven patients required only a single
round of this ITI regimen, while the remaining two patients
requiring a second iteration of the same ITI regimen, demon-
strated significantly lower antibody titers compared to what has
been described in CN patients treated with ERT monotherapy.
Not only did titers in our patients remain consistently lower than
those usually seen in CN patients on monotherapy, but they were
even lower than those seen in so-called low-titer CRIM-positive
(LTCP) patients who generally respond well to ERT [9].
While the majority of CN IPD patients develop HSAT, there
are rare case reports of CN IPD patients who do not develop
HSAT and can have a variable immunological response to ERT
[17–19]. With multiple factors leading to HSAT formation [9], it
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Figure 5. Kaplan-Meier survival curve showing comparison of ventilator-free survival CRIM-negative (CN) ERT monotherapy
(n=11) versus CN ERT+ITI (n =7) treated patients. *Three patients in the CN ERT+ITI group began the study invasively ventilated, became
ventilator-free with treatment, and are currently still alive and ventilator-free. In contrast, all CN patients in ERT monotherapy treated group were
invasive ventilator-free at baseline. This observation suggests that in some cases ERT+ITI can even reverse ventilator dependence in CN Pompe
patients.
doi:10.1371/journal.pone.0067052.g005
Figure 6. Comparison of anti-rhGAA IgG antibody titers seen over time in CRIM-negative (CN) treated with ERT monotherapy (n=8)
versus CN ERT+ITI (n =7) treated patients.
doi:10.1371/journal.pone.0067052.g006
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is not at this time possible to predict which CN IPD patients will
develop HSAT and which will not. Until recently, there have been
no known reports of a method to control HSAT once formed.
Different combinations of long-term immune modulation with
cyclophosphamide, IVIG, plasmapheresis, and increased doses of
rhGAA 6 rituximab have failed to induce immune tolerance in
the setting of an entrenched immune response in CN IPD patients
mainly due to inability of those agents/combinations to target
antibody-secreting long-lived plasma cells [12,13]. The only
successful attempt at counteracting HSAT utilized a multi-
pronged regimen using bortezomib to target plasma cells and
rituximab, methotrexate, and IVIG to target naı¨ve and memory
B- and T- cells. Yet, the duration and intensity of immune
modulation required to counteract the entrenched immune
response in the HSAT setting is relatively intense and long [20].
Therefore, rapid prediction of CN status based on GAA mutations
and the earliest possible initiation of ERT+ITI is required to
optimize long-term clinical outcomes by avoiding cumulative
doses of ITI and thus improved safety.
In this treatment algorithm, the ITI regimen included a short
course of rituximab, low-dose methotrexate and IVIG. While the
exact mechanism by which this regimen induces tolerance is not
known, it is believed that the suppression and/or elimination of B-
and T-cell populations responsible for antibody formation, with
simultaneous up regulation of regulatory T-cells (Tregs) and/or
regulatory B-cells (Bregs), is important for its success in diminishing
the immune response to rhGAA [14]. The ITI regimen described
here thus targets immune cells at different levels of the pathway
leading to plasma cell formation which is the source of sustained
antibody production. The mechanism by which this regimen
induces tolerance warrants further investigation using in vitro
assays to assess immunologic parameters of tolerance in patient
samples and appropriate animal models. It should be noted that all
patients, except one (patient 4), were placed on monthly IVIG
because of its known immunomodulatory effect [21], and also to
provide passive immunity during the period of immune suppres-
sion. However, whether IVIG is important in tolerance induction
in this setting remains to be investigated.
Since the introduction of ERT for Pompe disease, awareness
and early diagnosis have gained importance. Because the therapy
is most effective when started early, and methods for dried
bloodspot screening for Pompe disease are currently being used to
diagnose Pompe disease, newborn screening (NBS) has become a
reality in countries such as Taiwan and in several states in the US
[22]. In IPD it is vital to commence ERT at the earliest time point
possible due to the attendant risks associated with the development
of IPD-relevant complications, especially cardiorespiratory failure
followed by premature death. The most important and widely
accepted goal of newborn screening is to improve health outcomes
in the screened population of newborns. Given this goal, screening
makes sense only if early detection and treatment will lead to
better health outcomes than would be possible if treatment were
delayed until the condition became symptomatic or if treatment
outcomes are suboptimal despite early start [23]. CN IPD
represents the latter category as there is clear evidence that
without immune modulation, clinical outcome for CN IPD
patients treated with ERT alone is dismal due to formation of
HSAT against ERT [8,9]. While the majority of Pompe cases
identified through NBS in Taiwan are CRIM-positive [7],
approximately 25.1% of newly diagnosed Pompe cases in US
and other parts of the world are CN [15], making a diagnostic and
treatment approach which is safe and feasible, like the one
described here, even more important.
There are potential limitations specifically related to the ITI
regimen reported herein. In particular, this ITI regimen (like most
other chemotherapeutic regimens) is relatively non-antigen-specif-
ic and has the potential to cause generalized and significant
immune suppression. Thus, live vaccines cannot be administered
until there is full CD19% recovery and this makes infection with
opportunistic pathogens a potential complication that requires
close monitoring. Surprisingly, even when administered recur-
rently over long periods of time [10] very few reports of severe life
threatening infections have been reported. This may well be
attributable to the use of IVIG which is known to protect against
infectious agents in the setting of severe immune suppression while
paradoxically acting as an immunomodulatory agent that may
enhance immune tolerance [24]. Nonetheless, if severe, life-
threatening infections do arise, cessation of ITI could be required
and must be balanced against the risks inherently imposed by a
CRIM-negative status despite administration of ERT.
Another limitation is the potential need for implementation of
more than a single cycle of the regimen, specifically if there is a
breakthrough in anti-rhGAA IgG titers. In this study, two of the
seven patients required more than one administration of ITI
regimen. These patients may have FcR polymorphisms that
diminish the efficacy of rituximab [25] or other factors that caused
a more rapid progression of the immune response such that long
lived plasma cells are mediating the response.
Although the ITI treatment described here prolongs survival
and improves significant overall clinical outcomes, closer exam-
ination clearly demonstrates residual muscle weakness and gross
motor function below age-appropriate levels along with feeding
difficulties. However, even in long term CRIM positive survivors,
despite long-term treatment with ERT, similar issues are noted
[26]. Further follow-up of CN long-term survivors is needed to
better understand the overall outcomes of these patients.
The data presented here add to the two previously reported
cases of successful use of this ITI regimen in CN patients [10]. Use
of the protocol described herein is designed to take place over a
relatively brief period of time, and the agents employed have been
used extensively for a broad range of conditions, including those in
the pediatric population specifically. Moreover, CD19% is
associated with the degree of immune suppression and is a useful
marker for monitoring the status of immune suppression, but not
of immune tolerance. In this study, no patients experienced any
major side effects. Moreover, no major illnesses or hospitalizations
were directly attributed to the implementation of this protocol, and
it was possible to administer vaccines as scheduled upon recovery
of CD19 counts. Other approaches to immune tolerance
induction, such as non-depleting anti-CD4 mAb, gene therapy,
or agents that are antigen specific may prove highly efficacious and
avoid prolonged general immune suppression [14]. The algorithm
described here will serve as a paradigm going forward. The
combination of B- and T-cell targeting agents used in these
patients appears to be both safe and efficacious. This regimen,
shows promise in altering the natural history of CN IPD patients,
and allows for full derivation of the long-term clinical benefits of
ERT.
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